<p><img src="https://imageproxy.pbkrs.com/https://s.yimg.com/ny/api/res/1.2/nidoXpgo_DE5FcJuCPCPdg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyNDI7aD03NzM-/https://media.zenfs.com/en/afp.com.sg/1c8ab2a5a906f485ca15d031ad455394?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://s.yimg.com/ny/api/res/1.2/nidoXpgo_DE5FcJuCPCPdg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyNDI7aD03NzM-/https://media.zenfs.com/en/afp.com.sg/1c8ab2a5a906f485ca15d031ad455394"/></p>
<p>礼来的新型减肥药避免了注射的需要（SCOTT OLSON）</p>
<p>一项研究周四表示，这种每日服用的药丸比目前可用的减肥药便宜且更易服用，帮助人们在近 18 个月内减掉约十分之一的体重。</p>
<p>一种新一代的抑制食欲药物，称为 GLP-1 激动剂，包括热门品牌 Ozempic 和 Mounjaro，近年来变得极为流行。然而，这些治疗方法需要定期注射、冷藏，并且可能非常昂贵。</p>
<p>在巨额资金的推动下，制药公司竞相推出一种更简单的药丸，以利用 GLP-1 的减肥功效。</p>
<p>周四发表在《柳叶刀》医学杂志上的研究测试了一种名为 orforglipron 的新型无针药物，该药物由美国制药巨头礼来开发，礼来也生产 Mounjaro。</p>
<p>来自 10 个国家的超过 1500 名患有肥胖和 2 型糖尿病的成年人每日服用这种药丸，并接受健康饮食和锻炼的建议。</p>
<p>根据研究，服用最高剂量 36 毫克的参与者在 72 周后减掉了约 10% 的体重，而服用安慰剂的组别仅减掉了 2%。</p>
<p>这与今年早些时候发布的研究相似，该研究发现，肥胖但没有糖尿病的人在服用这种药丸时减掉了约 12% 的体重。</p>
<p>这些数字仍然远低于服用每周注射的 Mounjaro 的人的 22% 的体重减轻。</p>
<p>在最新的试验中观察到的副作用与已观察到的注射型 GLP-1 药物相似，包括恶心、呕吐、便秘和腹泻，尤其是在较高剂量时。</p>
<p>- '令人兴奋' -</p>
<p>&#34;拥有一种能够提供双位数减重的口服药物令人兴奋，平均减重为 23 磅（10 公斤），&#34; 研究首席作者德博拉·霍恩（Deborah Horn）在一份声明中表示。</p>
<p>如果 orforglipron 获得美国食品和药物管理局的批准，它预计将在 2026 年以显著低于当前注射药物的成本上市，&#34;她补充道。</p>
<p>在美国，注射型 GLP-1 的费用可能超过每月 1000 美元。一些专家呼吁制药公司在较贫穷的国家推出便宜的仿制药版本——研究表明这些药物可以以每月 4 美元的成本生产——以拯救更多生命。</p>
<p>根据世界卫生组织的数据，2021 年全球因肥胖或超重相关疾病死亡的人数超过 370 万人，超过了疟疾、结核病和艾滋病的总和。</p>
<p>GLP-1 药物最初是为糖尿病开发的，但研究表明它们可能有助于解决越来越多的健康问题，包括心脏病、睡眠呼吸暂停甚至成瘾。</p>
<p>pan/dl/jxb</p>

礼来

<p>根据《柳叶刀》上发表的一项研究，礼来公司开发的一种新型每日药丸，名为 orforglipron，帮助人们在 18 个月内减轻约 10% 的体重。这种药丸比目前的减肥药更便宜且更易于服用，如果获得 FDA 批准，预计将在 2026 年上市。该研究涉及超过 1500 名患有肥胖症和 2 型糖尿病的成年人。副作用包括恶心、呕吐、便秘和腹泻</p>

<p><img src="https://imageproxy.pbkrs.com/https://s.yimg.com/ny/api/res/1.2/nidoXpgo_DE5FcJuCPCPdg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyNDI7aD03NzM-/https://media.zenfs.com/en/afp.com.sg/1c8ab2a5a906f485ca15d031ad455394" alt="" original-src="https://s.yimg.com/ny/api/res/1.2/nidoXpgo_DE5FcJuCPCPdg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyNDI7aD03NzM-/https://media.zenfs.com/en/afp.com.sg/1c8ab2a5a906f485ca15d031ad455394"/></p>
<p>Eli Lilly's new weight loss pill avoids the need for injections (SCOTT OLSON)</p>
<div class="lb-trans"><p>礼来的新型减肥药避免了注射的需要（SCOTT OLSON）</p>
</div><p>A daily pill that is cheaper and easier to take than currently available weight loss drugs helps people lose around a tenth of their body weight over nearly 18 months, a study said Thursday.</p>
<div class="lb-trans"><p>一项研究周四表示，这种每日服用的药丸比目前可用的减肥药便宜且更易服用，帮助人们在近 18 个月内减掉约十分之一的体重。</p>
</div><p>A new generation of appetite-suppressing drugs called GLP-1 agonists -- which includes blockbuster brands Ozempic and Mounjaro -- has become massively popular in recent years. However these treatments require regular injections, refrigeration and can be prohibitively expensive.</p>
<div class="lb-trans"><p>一种新一代的抑制食欲药物，称为 GLP-1 激动剂，包括热门品牌 Ozempic 和 Mounjaro，近年来变得极为流行。然而，这些治疗方法需要定期注射、冷藏，并且可能非常昂贵。</p>
</div><p>With an immense amount of money at stake, pharmaceutical firms have been racing to be the first to market with a simpler pill that harnesses GLP-1's weight loss powers.</p>
<div class="lb-trans"><p>在巨额资金的推动下，制药公司竞相推出一种更简单的药丸，以利用 GLP-1 的减肥功效。</p>
</div><p>The study published in The Lancet medical journal on Thursday tested out a new needle-free drug called orforglipron developed by US pharma giant Eli Lilly, which also makes Mounjaro.</p>
<div class="lb-trans"><p>周四发表在《柳叶刀》医学杂志上的研究测试了一种名为 orforglipron 的新型无针药物，该药物由美国制药巨头礼来开发，礼来也生产 Mounjaro。</p>
</div><p>More than 1,500 adults across 10 countries with both obesity and type 2 diabetes took the pill daily alongside advice to eat a healthy diet and exercise.</p>
<div class="lb-trans"><p>来自 10 个国家的超过 1500 名患有肥胖和 2 型糖尿病的成年人每日服用这种药丸，并接受健康饮食和锻炼的建议。</p>
</div><p>Participants on the highest dose of 36 milligrams lost around 10 percent of their body weight after 72 weeks, compared to two percent for the group taking a placebo, according to the study.</p>
<div class="lb-trans"><p>根据研究，服用最高剂量 36 毫克的参与者在 72 周后减掉了约 10% 的体重，而服用安慰剂的组别仅减掉了 2%。</p>
</div><p>This is similar to research published earlier this year that found that people with obesity but not diabetes lost around 12 percent of their body weight while taking the pill.</p>
<div class="lb-trans"><p>这与今年早些时候发布的研究相似，该研究发现，肥胖但没有糖尿病的人在服用这种药丸时减掉了约 12% 的体重。</p>
</div><p>These figures are still well below the 22 percent of body weight lost by people taking the weekly injectable Mounjaro over the same time period.</p>
<div class="lb-trans"><p>这些数字仍然远低于服用每周注射的 Mounjaro 的人的 22% 的体重减轻。</p>
</div><p>The side effects seen during the latest trial reflected those already observed for injectable GLP-1 drugs, including nausea, vomiting, constipation and diarrhoea -- particularly at higher doses.</p>
<div class="lb-trans"><p>在最新的试验中观察到的副作用与已观察到的注射型 GLP-1 药物相似，包括恶心、呕吐、便秘和腹泻，尤其是在较高剂量时。</p>
</div><p>- 'Exciting' -</p>
<div class="lb-trans"><p>- '令人兴奋' -</p>
</div><p>&#34;It is exciting to have an oral medication that provides double-digit weight loss, which on average was 23 pounds (10 kilograms),&#34; lead study author Deborah Horn of UTHealth Houston said in a statement.</p>
<div class="lb-trans"><p>&#34;拥有一种能够提供双位数减重的口服药物令人兴奋，平均减重为 23 磅（10 公斤），&#34; 研究首席作者德博拉·霍恩（Deborah Horn）在一份声明中表示。</p>
</div><p>If orforglipron is approved by the US Food and Drug Administration, it is &#34;scheduled to be available in 2026 at a significantly decreased cost compared to current injectables&#34;, she added.</p>
<div class="lb-trans"><p>如果 orforglipron 获得美国食品和药物管理局的批准，它预计将在 2026 年以显著低于当前注射药物的成本上市，&#34;她补充道。</p>
</div><p>Injectable GLP-1s can cost over $1,000 a month in the US. Some experts have called for pharma firms to make cheap generic versions -- which research shows can be produced for $4 a month -- available in poorer nations where they could save the most lives.</p>
<div class="lb-trans"><p>在美国，注射型 GLP-1 的费用可能超过每月 1000 美元。一些专家呼吁制药公司在较贫穷的国家推出便宜的仿制药版本——研究表明这些药物可以以每月 4 美元的成本生产——以拯救更多生命。</p>
</div><p>More than 3.7 million people died from illnesses related to obesity or being overweight globally in 2021 -- more than malaria, tuberculosis and HIV combined, according to the World Health Organization.</p>
<div class="lb-trans"><p>根据世界卫生组织的数据，2021 年全球因肥胖或超重相关疾病死亡的人数超过 370 万人，超过了疟疾、结核病和艾滋病的总和。</p>
</div><p>GLP-1 drugs were originally developed for diabetes but research has suggested they could help with an expanding range of health problems including heart disease, sleep apnoea and even addiction.</p>
<div class="lb-trans"><p>GLP-1 药物最初是为糖尿病开发的，但研究表明它们可能有助于解决越来越多的健康问题，包括心脏病、睡眠呼吸暂停甚至成瘾。</p>
</div><p>pan/dl/jxb</p>
<div class="lb-trans"><p>pan/dl/jxb</p>
</div>

研究表明，每日服用的药丸可以帮助人们在 18 个月内减轻 10% 的体重